(Q33377327)

English

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Yasuhiro Oki

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michinori Ogura

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Harumi Kato

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Ako Kikuchi

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hirofumi Taji

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yoshitoyo Kagami

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Aya Oshiro

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Akane Tsujimura

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kazuhito Yamamoto

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yasuo Morishima

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

7 November 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

99

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

179-184

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00662.X

21 January 2018

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00662.X

21 January 2018

Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00662.X

21 January 2018

Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1349-7006.2007.00662.X

21 January 2018

Identifiers

10.1111/J.1349-7006.2007.00662.X

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33377327&oldid=1959172099"